Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of adults with a deleterious BRCA mutation (germline and/or ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer be controlled with hormone therapy. Even in such situations, effective ...

Hormonal changes in a man's aging body can cause the prostate to grow—resulting in urinary problems since the gland is wrapped around the urethra, as seen in this image taken from Asklepios Atlas of ...

Q: Recently, a 47-year-old asymptomatic patient had a random prostate-specific antigen (PSA) level of 5.32 ng/mL. A repeat assay the following day was 6.10. All previous PSAs over a seven-year period ...

Prostate involvement was first reported in IgG4-RD approximately 2 decades ago and comprises only 9.6% of cases. A male patient in his 7os presented with isolated prostatitis associated with ...